AbbVie has reported global net revenues of nearly $14bn for the second quarter (Q2) of 2021, reflecting a 33.9% surge on a reported basis compared to $10.42bn in the same period last year.

Net revenue grew 19.3% on a comparable operational basis in Q2 2021.

For the quarter ended 30 June 2021, the GAAP diluted earnings per share (EPS) slightly declined to $0.42 from $0.46 in Q2 last year.

Adjusted diluted EPS, excluding specified items, rose to $3.11 in the second quarter of 2021, as against $2.34 in the prior-year quarter.

Global net revenues from the immunology portfolio for the Q2 of this year totalled $6.12bn, witnessing a growth of 15.1% on a reported basis and 13.8% on a comparable operational basis.

In the US region, Humira (adalimumab) generated net revenues of $4.26bn, a 7.1% increase on a reported basis in Q2 2021.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Furthermore, Humira’s international net revenues decreased 6% on a reported basis to $811m, owing to biosimilar competition.

During the quarter, the hematologic oncology and neuroscience portfolios generated $1.81bn and $1.5bn in global net revenues, up 14.1% and 98.8%, respectively, on a reported basis.

Aesthetics portfolio’s global net revenues grew more than 100% on a reported basis to $1.43bn.

The company added that overall net revenues of eye care and women’s health businesses increased by more than 100% and 29.9%, respectively, while other major products saw a 19.9% rise on a reported basis.

AbbVie chairman and CEO Richard Gonzalez said: “AbbVie delivered another strong quarter and our business continues to perform extremely well across the portfolio, with AbbVie’s new immunology assets contributing more than $1bn of combined sales in the quarter.

“The Allergan integration also continues to track exceptionally well, with both the neuroscience and aesthetics portfolios delivering double-digit sequential growth.”

AbbVie has updated its GAAP diluted EPS guidance for the full year 2021 from $7.27 to $7.47 to $6.04 to $6.14.

Furthermore, the adjusted diluted EPS for the full-year 2021 was increased to $12.52 t o$12.62 from $12.37 to $12.57.

Last month, the company expanded its partnership with Calico Life Sciences to discover, develop and commercialise novel treatments for age-related diseases such as neurodegeneration and cancer.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now